Searched for
COHANCE LIFESCIENCES
Cohance Lifesciences to invest USD 18 mn in NJ Bio, Aruka BioCohance Lifesciences announced an eighteen million dollar investment to strengthen its antibody-drug conjugate strategy. This includes thir...- Can Symbiotec Pharmalab IPO deliver long-term growth for high-risk investors?Symbiotec Pharmalab plans a ₹150 crore IPO to repay debt and expand operations. The company holds a global leadership position in corticost...
- Cipla Q4 net profit slumps 55% YoY to Rs 555 crore, full-year PAT down 26%Pharma major Cipla announced a significant 55% drop in its net profit for the March quarter. Total income also saw a 3% decrease. For the f...
- Cohance Lifesciences shares slip 7% after Jefferies cuts target price, downgrades on weak Q4Cohance Lifesciences shares dropped significantly after reporting an 84% year-on-year decline in March-quarter net profit. Jefferies downgr...
- Cohance Lifesciences shares rocket 43% in just 2 trading sessions. Here’s what is fuelling the surgeCohance Lifesciences shares surged over 43% in two days following the appointment of former Cipla CEO Umang Vohra as Executive Chairman and...
- Cohance Lifesciences shares skyrocket 20% on hiring former Cipla CEO Umang VohraShares of Cohance Lifesciences surged 20% on Monday after the appointment of former Cipla CEO Umang Vohra as its new Executive Chairman and...
- Stocks to buy in 2025 for long term: Cohance Lifesciences, Divi’s Lab among 5 stocks that could give 10-30% returnBrokerages remain upbeat on select stocks across sectors, rolling out fresh Buy calls with healthy upside potential.
- Cohance Lifesciences and other pharma stocks jump up to 5% after Jefferies initiates Buy recommendationCohance Lifesciences, Divi’s Laboratories, and SAI Life Sciences rallied after Jefferies initiated coverage with ‘Buy’ ratings, citing stro...
- Cohance Lifesciences announces $10 million investment in US-based armCohance Lifesciences is investing USD 10 million to expand bioconjugation capabilities at its US subsidiary, NJ Bio, enhancing its ADC solu...
- Exploring the Growth Potential of the Indian Pharmaceutical SectorThe Indian pharmaceutical sector is poised for significant growth, driven by favorable trade agreements and increasing global demand for ge...
- Suven, Cohance aim to double combined business revenue to Rs 6,000 cr by FY29Suven Pharmaceuticals and Cohance Lifesciences plan to merge and aim to double their revenue to Rs 6,000 crore by FY29 through organic and ...
- Pharma raw material makers in race to tank up on CXO talentSome of these PE-owned platform companies include Advent International-led Cohance Lifesciences / Suven Pharma, PAG and CX Partners-funded ...
- Merger effect! Suven Pharma shares jump 15% in 2 daysAfter the merger becomes effective, all shareholders of Cohance will be issued shares of Suven at the ratio of 11 shares of Suven for every...
- Suven, with Cohance and more, wants to become a CDMO powerhouse: Annaswamy Vaidheesh, executive chairman"We want to be a diversified, end-to-end capability outsourcing partner, serving customers from development to commercial scale. Doing this...
- Suven Pharmaceuticals shares soar 13% on proposed merger with Cohance LifesciencesShares of Suven Pharmaceuticals surged 13% on the NSE after proposing a merger with Cohance Lifesciences to strengthen its CDMO industry po...
- Suven-Cohance Lifesciences merger announced to create 1st listed PE-led contract manufacturer in Indian pharmaSuven has been 50% owned by Advent since 2022 acquisition, with the remaining with public and institutional shareholders while Cohance is w...
- Suven Pharma, Cohance Lifesciences to merge to bolster CDMO businessPromoter of Suven Pharma, Advent International, had said last year that it would merge the two businesses post the buyout of its significan...
- ADIA, HarbourVest eye minor stake in CohanceADIA and HarbourVest are in discussions to acquire a minority stake in Cohance Lifesciences, a pharmaceuticals platform owned by Advent Int...
- Suven Pharma falls 2% as Advent picks majority stake in the companyPost the completion of this acquisition, Advent intends to explore the merger of its portfolio company, Cohance Lifesciences with Suven, to...
- PE firm Advent names its India API, CDMO platform as Cohance LifesciencesThe US-based PE firm which is betting on India pharma, said that it intends to add more assets in the future with the vision to become one ...
Load More
